Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AAPG.O
stocks logo

AAPG.O

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast AAPG.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG.O is 49.00 USD with a low forecast of 47.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast AAPG.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG.O is 49.00 USD with a low forecast of 47.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.880
sliders
Low
47.00
Averages
49.00
High
51.00
Current: 32.880
sliders
Low
47.00
Averages
49.00
High
51.00
Oppenheimer
Matthew Biegler
Outperform
initiated
$45
2025-12-04
New
Reason
Oppenheimer
Matthew Biegler
Price Target
$45
2025-12-04
New
initiated
Outperform
Reason
Oppenheimer analyst Matthew Biegler initiated coverage of Ascentage Pharma with an Outperform rating and $45 price target. The firm believes Ascentage has the potential to become the next BeOne. To get there, they're taking a page from BeOne's playbook. Better drugs, focusing on chronic blood cancers with large TAMs, Oppenheimer argues, adding that olverembatinib looks like a best-in-class BCR-ABL inhibitor. Separately, Ascentage's BCL-2 inhibitor lisaftoclax is taking aim at BeOne's biggest market: Chronic Lymphocytic Leukemia. The firm believes lisaftoclax' tolerability could enable it to make inroads into an indication where other BCL-2 inhibitors have failed, namely Myelodysplastic syndrome.
Truist
Gregory Renza
Buy
initiated
$51
2025-11-24
Reason
Truist
Gregory Renza
Price Target
$51
2025-11-24
initiated
Buy
Reason
Truist analyst Gregory Renza initiated coverage of Ascentage Pharma with a Buy rating and $51 price target. The company's Lisaftoclax is differentiated by improved tolerability and accelerated 5-day dose ramp-up, which is clinically meaningful, according to key opinion leaders, the analyst tells investors in a research note. Growth in China depends on the NRDL inclusion by the end of 2027, and the firm views GLORA's readout 2025-end or 2026E as key to supporting U.S. expansion in second-line CLL/SLL, or chronic lymphocytic leukemia/small lymphocytic lymphoma, the firm added.
BTIG
Buy
initiated
$50
2025-11-10
Reason
BTIG
Price Target
$50
2025-11-10
initiated
Buy
Reason
BTIG initiated coverage of Ascentage Pharma with a Buy rating and $50 price target. The firm says Ascentage has a "validated" apoptosis-targeted platform and two late-stage assets, Olverembatinib and Lisaftoclax, to drive sustained commercial growth and valuation upside. BTIG views Ascentage as one of the "most compelling" China-based biopharma stocks. The company is positioned to for "sustainable global relevance" as it transitions from clinical-stage to commercial-scale, the analyst tells investors in a research note.
Piper Sandler
Biren Amin
Overweight
initiated
$48
2025-11-05
Reason
Piper Sandler
Biren Amin
Price Target
$48
2025-11-05
initiated
Overweight
Reason
Piper Sandler analyst Biren Amin initiated coverage of Ascentage Pharma with an Overweight rating and $48 price target. The company's two approved assets in China are now under evaluation in the U.S., the analyst tells investors in a research note. Piper projects $1.9B and $1B in peak risk-adjusted global revenues for olverembatinib and lisaftoclax, respectively.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ascentage Pharma Group International (AAPG.O) is -45.83, compared to its 5-year average forward P/E of -29.05. For a more detailed relative valuation and DCF analysis to assess Ascentage Pharma Group International 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-29.05
Current PE
-45.83
Overvalued PE
5.05
Undervalued PE
-63.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-150.32
Current EV/EBITDA
-493.76
Overvalued EV/EBITDA
58.51
Undervalued EV/EBITDA
-359.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
23.89
Current PS
17.10
Overvalued PS
32.70
Undervalued PS
15.08
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AAPG.O News & Events

Events Timeline

(ET)
2025-12-07
13:20:00
New
Ascentage Pharma Presents Latest Phase II Study Results of Lisaftoclax at ASH Meeting
select
2025-08-17 (ET)
2025-08-17
21:11:15
Ascentage Pharma receives clearance from U.S. FDA, EMA to conduct GLORA-4
select
2025-07-10 (ET)
2025-07-10
09:36:33
Ascentage Pharma announces China NMPA approval of lisaftoclax
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-07Newsfilter
Ascentage Pharma's Lisaftoclax Shows 62.5% ORR in BTK-Refractory CLL/SLL Patients
  • Significant Clinical Efficacy: Lisaftoclax achieved a 62.5% objective response rate (ORR) in 77 heavily pretreated BTK-refractory R/R CLL/SLL patients, underscoring its potential as a new treatment option, particularly among those with complex karyotypes.
  • No Tumor Lysis Syndrome: The median progression-free survival (PFS) was reported at 23.89 months, with no cases of tumor lysis syndrome observed, indicating a favorable safety profile suitable for heavily pretreated patients.
  • Addressing High-Risk Patients: Among the participants, 42.9% had complex karyotypes and 39% had del(17p)/TP53 mutations, yet Lisaftoclax demonstrated strong efficacy in these high-risk patients, fulfilling an urgent clinical need for breakthrough therapies.
  • Advancing Global Registrational Studies: Ascentage is conducting four global registrational Phase III studies to evaluate Lisaftoclax across multiple indications, further solidifying its position in the global hematologic oncology landscape.
[object Object]
Preview
9.0
12-06Globenewswire
Ascentage Pharma's Lisaftoclax Shows 62.5% Response Rate in CLL/SLL Treatment
  • Significant Clinical Efficacy: Lisaftoclax achieved a 62.5% objective response rate in heavily pretreated BTK-refractory R/R CLL/SLL patients, underscoring its potential as a new treatment option, particularly among those with complex karyotypes.
  • Extended Survival: The drug demonstrated a median progression-free survival of 23.89 months in patients, with no tumor lysis syndrome reported, indicating a favorable safety profile and the ability to provide new hope for high-risk patients.
  • High-Risk Patient Response: Among 77 enrolled patients, 42.9% had complex karyotypes, and despite these high-risk factors, Lisaftoclax exhibited strong therapeutic potential, highlighting its importance in addressing unmet medical needs.
  • Advancement of Global Registrational Studies: Ascentage Pharma is conducting four global registrational Phase III studies to evaluate Lisaftoclax across multiple indications, further solidifying its position in the global oncology treatment landscape.
[object Object]
Preview
2.0
12-05Globenewswire
Ascentage Pharma Receives FDA and EMA Clearance for Global Phase III Trial of Olverembatinib
  • Global Trial Launch: Ascentage Pharma's olverembatinib combination chemotherapy has received FDA and EMA clearance, marking the initiation of the global registrational Phase III trial POLARIS-1, aimed at accelerating treatment for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
  • Impressive Clinical Data: At the ASH 2025 meeting, data revealed that among treatment-naïve patients receiving olverembatinib, the minimal residual disease (MRD) negativity rate and molecular MRD-negative complete response rate reached approximately 65% after three treatment cycles, significantly outperforming other drugs in the same class, showcasing its superior efficacy.
  • Significant Market Potential: Philadelphia chromosome-positive acute lymphoblastic leukemia accounts for 20%-30% of all ALL cases in adults, with a notably high incidence in the elderly, indicating substantial market demand and potential revenue for olverembatinib.
  • Strategic Partnership Outlook: Ascentage signed an exclusive option agreement with Takeda, which, if exercised, would grant Takeda global rights to develop and commercialize olverembatinib outside of mainland China, Hong Kong, Macau, and Taiwan, further expanding its international market presence.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ascentage Pharma Group International (AAPG.O) stock price today?

The current price of AAPG.O is 32.88 USD — it has increased 7.1 % in the last trading day.

arrow icon

What is Ascentage Pharma Group International (AAPG.O)'s business?

Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.

arrow icon

What is the price predicton of AAPG.O Stock?

Wall Street analysts forecast AAPG.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG.O is 49.00 USD with a low forecast of 47.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ascentage Pharma Group International (AAPG.O)'s revenue for the last quarter?

Ascentage Pharma Group International revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Ascentage Pharma Group International (AAPG.O)'s earnings per share (EPS) for the last quarter?

Ascentage Pharma Group International. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Ascentage Pharma Group International (AAPG.O)'s fundamentals?

The market is revising Downward the revenue expectations for Ascentage Pharma Group International (AAPG) for FY2025, with the revenue forecasts being adjusted by -4.07% over the past three months. During the same period, the stock price has changed by -19.88%.
arrow icon

How many employees does Ascentage Pharma Group International (AAPG.O). have?

Ascentage Pharma Group International (AAPG.O) has 0 emplpoyees as of December 08 2025.

arrow icon

What is Ascentage Pharma Group International (AAPG.O) market cap?

Today AAPG.O has the market capitalization of 3.07B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free